Fig. 1. Aromatic ligands forming cation–π interactions with the target protein: (A) sorafenib complexed with Human p38 MAP kinase, (B) lapatinib in complex with ErbB4 kinase, (C) Conway and co-workers' dihydroquinoxalinone inhibitor of the CREBBP bromodomain.